GTEC 最新進展

1)該公司CEO決定12月來美國路展(ROAD SHOW)，進一步向美國各界推廣該公司。

2)計劃在未來的幾個季度中將該股票推向更高一層美國交易平台，屆時該股價毫無
疑問會數倍於現在的價格。

3)新藥物寶寶樂已經上市，還有更多的新葯已送交審批，可於近期上市。

4)該公司藥品走高端路線，門檻兒較高，非一般小公司可參與競爭。保持該公司的
利潤空間。

5)與中國科學院微生物研究所達成合作協議，可優先享用專利產品。既節省了研究
費用，又提高了知名度。

如果您打算做投資，現在該公司股票真的很便宜。今天最高價也不過0.313/SHARE。


請您認真研究，再做定奪。


Letter to Shareholders From the CEO and Chairman of the Board of Genesis
Pharmaceuticals
Tuesday November 20, 12:50 pm ET
NEW YORK, Nov. 20, 2007 (PRIME NEWSWIRE) -- The following is being issued
by Genesis Pharmaceuticals Enterprises, Inc. (OTC BB:GTEC.OB - News):
Dear Shareholders:
We are very pleased to have successfully completed the merger of Laiyang
Jiangbo Pharmaceuticals Co., Ltd. (``Laiyang Jiangbo'') with Genesis Technology
Group, Ltd. -- resulting in a new public company called Genesis Pharmaceuticals
Enterprises, Inc. I want to take a moment to reach out to all of our shareholders
in order to review where we are, how we got here and what shareholders may
expect in the future.
ADVERTISEMENT
I am pleased to report that the final terms of the merger were completed
on October 1, 2007. As a result of the merger, Genesis Pharmaceuticals Enterprises,
Inc. is listed on the OTC Bulletin Board and trades under the symbol ``GTEC.
''
The new company is a pharmaceutical company whose primary operations are
those of our operating subsidiary Laiyang Jiangbo. Founded in 2003, Laiyang
Jiangbo focuses on the research, development, production, marketing and
sales of new and sophisticated pharmaceutical products in the People's Republic
of China. We have rapidly established ourselves as a leader in drug development
and modern marketing in China, and our lead drugs enjoy significant market
share in their categories.
Our company has a very strong financial profile
For its fiscal year ended June 30, 2007, Laiyang Jiangbo reported revenue
of US$76.2 million, up by 55% over the prior year. Gross profit increased
by 64% to US$55 million, and our operating income increased by 53% to US$18.3
million, over the same period. For fiscal 2007, we reported audited net
income of US$22.1 million, inclusive of a one-time US$9.9 million credit
for a corporate and VAT tax exemption we received from the Chinese government.
Our fiscal condition is also very solid, with total assets of US$55.4 million,
shareholders' equity of US$27.3 million, and cash on hand of US$17.7 million,
as of June 30, 2007.
Our company is well positioned in the very attractive China pharmaceutical
market
Pharmaceutical demand in China is forecast to expand by more than 13% annually
to reach about US$51 billion by 2010. Strong economic growth, changing demographic
patterns, and the reform and expansion of health care systems are expected
to drive greater demand for drugs. Genesis Pharmaceuticals is well positioned
to meet that increased demand.
Our current products are approved by the Chinese State Food and Drug Administration
and include Clarithromycin sustained-release tablets, Itopride Hydrochloride
granules, Ciprofloxacin Hydrochloride tablets and Paracetamol tablets. We
started sales of Baobaole chewable tablets this month, in November.
We have a strong and growing pipeline of Class 1 drugs
A research and marketing driven organization, our company is driven to bring
new drugs to market that can significantly improve clinical outcomes for
patients in major disease categories. Since 2005, our three major drugs
(Ciprofloxacin Hydrochloride, Paracetamol and Clarithromycin) have been
on the approved list for reimbursement by the national healthcare Insurance
Catalogue. A fourth drug (Itopride Hydochloride) is expected to get provincial
government approval soon, which will make it available to over 166 million
potential users. We aim to have all of our new drugs under development be
on government approval lists. This is very important to maximize the availability
of drugs to patients and revenue generating potential of our products. 
Genesis recently announced a US$5 million private placement financing for
the acquisition of a new Chinese Class 1 drug Ligustrazine Ferulic Acid
Acetate (``LFAA''), a cardiac cerebral vascular drug that is designed to
help reduce blood clotting and prevent platelets in the blood from clumping
together. Assuming that LFAA receives all of the necessary Chinese regulatory
approvals, the Company plans to put the drug into trial production in fiscal
year 2008, and expects fiscal year 2009 sales of US$9.9 million and fiscal
year 2010 sales of US$26.3 million.
We are adding new drugs to our product line to increase overall growth for
the company. We are currently seeking government approvals to produce Felodipine
Sustained Release Tablets, Radix Isatidis Dispersible Tablets, Yuandu Hanbi
Capsulesa and Bezoar Yijin Tablets. Drug sales have a lifecycle during which
competition often leads to decreasing profit margins over time. Our focus
going forward is on Chinese Class 1 drugs that often have high profit margins.
Manufacturing these sophisticated new drugs requires advanced technology,
which means competitors face high barriers to entry. We are committed to
having and using the latest technology to manufacture new sophisticated
drugs with high profit margins.
Genesis Pharmaceuticals Enterprises, Inc. will continue to grow by expanding
its distribution network of 440 full time and 620 part time representatives
throughout China. Sales to end users such as doctors and hospitals, and
not just distributors, help build brand recognition and customer loyalty.
Sales representatives will continue to sell existing and new products to
existing and new customers.
Our team is committed to operate at world class standards.
We have a strong management team in place, which has recently been enhanced
by the addition of a qualified Chief Financial Officer with U.S. GAAP experience,
Elsa Sung. Most of Genesis Pharmaceuticals' senior management has extensive
industry experience and has been in place since the founding of Laiyang
Jiangbo in 2003. They will ensure that Genesis Pharmaceuticals executes
its growth strategy.
Now, after completing our going public transaction, we are committed to
developing the human resources and systems required to meet our responsibilities
as a U.S. public company. We are committed to high quality disclosure and
shareholders will be able to observe management activities and obtain accurate
information about the Company through the company's website (http://www.genesis-
china.net/), which will soon be relaunched in both English and Chinese. 
We are committed to the highest level of corporate governance. Our new Board
of Directors consists of high level managers and independent Directors:


Cao Wubo          Chief Executive Officer and Chairman of the Board
Xu Haibo          Vice President, Chief Operating Officer and Director
Feng Xiaowei      Outside Director
Huang Lei         Outside Director
Ge Jian           Outside Director
Zhang Yihua       Outside Director
Rodrigo Arboleda  Outside Director (From Genesis Technology Group)
Robert Cain       Outside Director (From Genesis Technology Group)
Over the next several quarters we plan to take the steps required to move
Genesis Pharmaceuticals to a major stock market in the U.S. so as to attain
greater visibility with investors and the media and enhance the marketability
of our stock.
Genesis Pharmaceuticals' senior management plans to take a trip to the U.S.
in December 2007. This trip will give U.S. shareholders a chance to meet
with management and ask management questions about Genesis Pharmaceuticals.

I hope that this letter has given our new shareholders some sense of the
development of our company and our strategic direction. Our team looks forward
to updating you on our progress through regular conference calls and visits
to meet with our investors. In closing, I would like to thank our customers,
shareholders, directors and employees for the Company's present and future
success. Thanks to all of you for your continuing interest in Genesis Pharmaceuticals.

Cao Wubo, Chief Executive Officer and Chairman of the Board
Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Announces Cooperation Agreement with The Institute
of Microbiology, Chinese Academy of Sciences
Wednesday November 21, 8:30 am ET
LAIYANG, China, Nov. 21, 2007 (PRIME NEWSWIRE) -- Genesis Pharmaceuticals
Enterprises, Inc. (OTC BB:GTEC.OB - News) (``Genesis'' or the ``Company''),
a U.S. pharmaceutical company with its principal operations in the People's
Republic of China, today announced that it signed a cooperation agreement
with The Institute of Microbiology, Chinese Academy of Sciences (IMCAS),
a research institution in China that performs a wide spectrum of basic and
applied research in the field of microbiology.
ADVERTISEMENT
AAAccording to the cooperation agreement, Genesis and IMCAS will build
a ``Genesis Pharmaceuticals Industrialization Model'' to do joint research
with the goal of commercializing pharmaceutical discoveries. This Industrialization
Model is IMCAS' first cooperative arrangement with a pharmaceuticals manufacturing
company.
Genesis will fund the Industrialization Model's daily operations and research
and development activities. Once new drugs have completed a first stage
of experiments in the Industrialization Model, they will be delivered to
Genesis's factory for further testing to determine the viability of commercial
wide-scale production. Genesis' research and development staff will work
with researchers from IMCAS to resolve issues that arise during the process
of designing the manufacturing process for new drugs. Genesis will have
the first right to purchase patents for any products developed by the Industrialization
Model and IMCAS.
``We are very pleased that IMCAS chose Genesis to be its partner in the
commercialization of new drug discoveries,'' said Mr. Cao Wubo, Chairman
and CEO of Genesis Pharmaceuticals Enterprises, Inc. ``Because IMCAS is
the national leading research institution in the field of microbiology,
we believe collaboration will bring valuable research and develop expertise
to Genesis and strengthen our own R&D force. This will extend our company's
use of cutting edge technologies as well as solidify our leading position
in the Chinese pharmaceutical market.''
About IMCAS
The Institute of Microbiology, Chinese Academy of Sciences (IMCAS) was founded
on December 3, 1958. It is a national comprehensive research institution
that performs a wide spectrum of basic and applied research in the field
of microbiology. IMCAS hosts 300 faculty and staff, including 5 CAS academicians.
Currently, it has three key laboratories: State Key Laboratory of Microbial
Resources, State Key Laboratory of Plant Genomics, and CAS Key Laboratory
of Systematic Mycology and Lichenology as well as nine research centers which
carry out studies on microbial resources, microbial genomics, agricultural
biotechnology, bio-energy and industrial biotechnology, environmental biotechnology,
extremophiles, microbial metabolic engineering, molecular virology, and
molecular immunology, As the national leading research and development organization
in China, IMCAS successfully developed SARS vaccine.
As the national leading research institution in the field of microbiology,
the IMCAS is committed to the advancement of science and technology. During
the last 40 years, it has attained a number of developmental achievements
in molecular evolution, pathogenicity, and cross-species propagation, as
well as antiviral fields which can be the initial force for industrialization
process.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged
in the research, development, production, marketing and sales of pharmaceutical
products in the People's Republic of China. Its operations are located in
Northeast China in an Economic Development Zone in Laiyang City, Shandong
province. Genesis is a major pharmaceutical company in China producing tablets,
capsules, and granules for both western and Chinese herbal-based medical
drugs. The Company maintains a representative office in the U.S. For more
information, refer to http://www.Genesis-China.net
Safe Harbor Statement
Certain statements set forth in this press release constitute ``forward-looking
statements.'' Such statements are not guarantees of future performance and
are subject to risks and uncertainties that could cause the Company's actual
results and financial position to differ materially from those included
within the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's ability
to introduce, manufacture and distribute new drugs. Actual results may differ
materially from predicted results, and reported results should not be considered
as an indication of future performance. The potential risks and uncertainties
include, among others, the Company's ability to obtain raw materials needed
in manufacturing, the continuing employment of key employees, the failure
risks inherent in testing any new drug, the possibility that regulatory
approvals may be delayed or become unavailable, patent or licensing concerns
that may include litigation, direct competition from other manufacturers
and product obsolescence. More information about the potential factors that
could affect the Company's business and financial results is included in
the Company's filings, available via the United States Securities and Exchange
Commission.

Contact:
         Genesis Pharmaceuticals Enterprises, Inc.
         Ms. Elsa Sung, CFO                          
         877-895-3650, Ext. 701              
         info@Genesis-China.net

         CCG Elite Investor Relations, Inc.
         Mr. Crocker Coulson, President   
         +1-646-213-1915 (New York)         
         crocker.coulson@ccgir.com

暴富和風光，只屬於那些成功躍上納斯達克的企業。

　　11月的某一天，上海市高級人民法院，一個納斯達克上市的失敗案例在此終審落幕。

　　被告席上密密麻麻站了8位被告。而導演這個失敗案例的主角，則是一位身材矮小、皮膚黝黑、只會幾句英文的59歲台灣籍女人，謝長華。

　　平日里，她看上去只像一個普通的農村婦女，但總共有四家做著納斯達克夢的中國企業相信了她的遊說，並隨她一起夢碎於此。這個長達7年的惡夢，不僅斷送了企業的融資機會，還把負責人直接送入大獄。

　　一份文號為「(2007)滬高刑終字第21號」的終審判決文書下達，謝長華犯集資詐騙罪獲判無期徒刑，其餘被告也獲刑2至7年不等。

　　在通往納斯納克的道路上，這樣的失敗不是個案。

　　願者上鉤

　　謝長華的身份是恩麥聯(上海)諮詢有限公司(下簡稱恩麥聯公司)的董事長。

　　這家諮詢公司的母公司是註冊於英屬維爾京群島的恩麥聯國際集團公司(EN MARINE INTERNATIONAL GROUPING)，董事長為謝長華的丈夫黃某。

　　MARINE，意為水兵和艦隊，謝長華的納斯達克之旅就從這個有著美麗名字的離岸企業開始。

　　2001年4月，謝長華與蔣某結識。蔣是常州百老彙集團有限公司法定代表人，該企業是常州當地一家以商業房地產為主營業務的民營企業。

　　融資饑渴和上市神話碰撞出了火花。4年前的1997年，納斯達克駐中國的機構剛剛成立。4年後，在這個年過半百的老太太嘴裡，這四個字成了能提供源源不斷資金的「蓮花」。

　　在雙方簽訂的《諮詢協議》中，約定了上市方法：通過謝在美國內華達州購買一個殼公司，購入后更名為百老匯國際發展公司，經過經營后達到一定規模，並經美國證券交易委員會批准上市，設定每股面值為0.001美元。

　　在完成上述買殼上市的過程中，百老匯需向謝長華支付上市費用，在百老匯上市后，謝長華還將獲取新上市公司9%的股份。

　　2002年2月至2004年8月間，百老匯先後掏出真金白銀，共支付了26.65萬美元作為上市費用。

　　謝的第二個「客戶」是上海蘇鵬實業有限公司(以下簡稱「蘇鵬公司」)。

　　2003年下半年，謝長華通過加拿大籍人士劉某又結識了蘇鵬公司的總經理傅某，並於10月以英屬維爾京群島註冊的日升公司的名義，與蘇鵬公司簽訂了《諮詢協議書》。

　　從協議書來看，謝進一步提高了價碼。日升公司為蘇鵬公司購買用於直接在美國上市的殼公司，而殼公司上市后，20%的股份歸謝，蘇鵬公司35%，介紹人劉某15%，殼公司10%，審計師律師等20%。另外，蘇鵬公司還需要向日升公司支付諮詢費用。

　　法庭上提交的收據和口供證明，這筆已經支付的諮詢費用不低於150萬美元。

　　同樣的命運也落到了上海安基生物科技有限公司(下簡稱安基公司)和上海玉同葯業股份有限公司(下簡稱玉同公司)身上。不過這兩家公司都沒有支付諮詢費用和買殼費用，而是約定在上市成功之後，分給中介商一定的股權比例。

　　略有不同的是，給玉同公司做諮詢的並非謝長華，而是介紹謝與蘇鵬公司結識的加拿大籍人士劉某。在眼看謝發了大財之後，劉某也搖身成為包裝上市的諮詢商。

　　空殼股票
　　在簽署協議之後，謝長華就著手在美國物色殼公司。

　　在通過她在美國的兒子購入三家殼公司后，謝長華將其分別改名為百老匯美國發展公司、美國上海化工公司和安基美國生物有限公司。其中，購買美國上海化工公司的殼花費了30餘萬美元。

　　與普通借殼上市不同，在購入殼公司之後，謝長華並沒有建議國內公司對殼公司進行資產注入，而是轉而自製股票在國內進行一級半市場的交易。

　　謝長華開始遊說的2001年，中國股票的發行也正經歷著重大變革，由原來的行政審批改為核准制，地下「一級半」市場仍在最後的活躍期。

　　在股票術語中，發行市場叫一級市場，流通市場叫二級市場，一級半市場就是介於發行和流通的中間環節。因為有原本地方政府批准發行的內部職工股存在，內幕人士在知道股票上市的確切消息后，到公司職工手中低價購買職工股，待上市后牟取暴利，造就了一個混亂的一級半市場。

　　正是這個暴利的灰色市場給了謝長華啟發。一份長達62頁的刑事裁定書認為，「謝長華獲悉推銷國內『一級半市場』股權轉讓可獲取大額利潤，便起意利用國內上市公司欲赴美上市融資的迫切心理……實施詐騙」。

　　不同於其他「玩家」，謝的兒子長期浸潤美國，「國際視野」使得國內一級半的做法直接嫁接到了納斯達克。

　　謝長華先從加拿大寄回股票樣張，再根據樣張在國內製作印刷空白股票，並自行列印百老匯美國發展公司等內容，由謝的丈夫黃某在董事會主席一欄簽字。

　　「空殼股票」製成之後，2003年3月起，恩麥聯公司就委託中介公司上海天成投資實業有限公司(以下簡稱「天成公司」)銷售這些股票，天成公司收取0.7美元／股的傭金。

　　天成公司租借了浦東大道、漢口路等多處高檔寫字樓，以2.2美元或者18.22元人民幣一股的價格推銷這些「空殼股票」，承諾這些股票將在2004年1月1日之前在納斯達克市場上市，上市后即可交易且前5個交易日股價不低於4美元／股。同時，天成公司還出具書面承諾，如未能上市，天成公司將全額退還股票認購款。

　　言之鑿鑿之下，66位投資者買入了這堆製造出來的「股票」。

　　曾介紹謝與蘇鵬公司相識的加拿大籍人士劉某也參照謝長華的模式，租賃寫字樓，預售自己在美國上海化工公司上市后所擁有的15%股權，以作為受讓蘇鵬公司大股東股權的資金來源。

　　在運作安基公司上市時，謝長華連買殼之舉都迅速跳過。安基美國生物有限公司在案發時還沒有和殼公司合併，直接自製股票在國內尋找買者。

　　令人驚訝的是，為了配合賣股票，心繫納斯達克的蘇鵬公司也加入了這個行列。

　　2004年，蘇鵬公司四次在上海某權威證券媒體上刊登公告稱，蘇鵬公司已經全面收購交易代碼為「AXXC」的美國公司，暫定於2004年9月底以美國上海化工的名稱在納斯達克OTTCBB掛牌交易，後分別更改為2004年底之前在納斯達克小型資本市場和納斯納克主板市場掛牌交易。

　　截至記者發稿時，百老匯國際公司的股票銷售收入達519萬元，美國上海化工股票銷售收入2358萬元，安基美國股票收入741萬元，美國玉同股票收入505萬元。在這4000萬餘元的銷售額背後，盲目投資人數高達670人之多。

　　粉單真相

　　在每個協議中，謝長華都小心翼翼地註明將企業到納斯達克OTTCBB櫃檯或者粉單市場(PINK SHEETS)上市。

　　在法庭上，被告出示了經過公證的雅虎財經網和粉單市場網上搜索所得的美國上海化工公司情況及USCJ.PK的行情走勢圖，證實其確在美國納斯達克的粉單市場交易，2006年9月29日的交易價為0.21美元。

　　但這樣的交易並非納斯達克主板交易。納斯達克市場包括第一市場、小資本市場、場外櫃檯交易市場(OTCBB)和「粉單市場」(PINK SHEETS)。

　　其中，粉單市場是一個電子報價系統，級別處於末端，只有做市商之間可以交易。而OTTCBB市場是一個電子交易系統，沒有掛牌條件和標準，不提供自動交易執行體系，也不與證券發行機構發生關係。兩者均屬於櫃檯交易，多是每股價格僅幾美分的垃圾股，並非上市公司。

　　由於四家國內企業都沒有向殼公司注入資產，所以謝長華許諾的在納斯達克主板上市根本無法兌現，4美元／股的股價也是空口之言。

　　謝幕之前，由於投資者的賬戶內遲遲沒有股票入賬，謝長華為了平息投資者的質疑，讓其子從美國粉單市場購買了美國上海化工公司的股票，轉入部分投資者賬戶。劉某也將部分投資者的空殼美國上海化工股票，換成了在OTTCBB櫃檯交易的美國玉同股票。

　　根據前任納斯達克駐中國首席代表黃華國曾經提供的數據，目前在OTCBB上擱置的中國公司大概有上百家，其中未籌到資金並被滯留的約佔95%以上。

　　「很多中國企業不夠條件但急於上市,現在去OTCBB的基本都屬這種情況。」黃華國曾向本報介紹,「企業先在OTCBB經過充分培養,待市場表現贏得投資者認同后再向主板市場攀升也不失為上策」,黃華國說。

　　但問題是,相當多的中國企業在OTCBB上收購了「殼」之後卻長時間滯留。中國企業到美國上市，尤其是借殼上市過程中，程序和法律都非常複雜，作為一般投資者難以做出準確判斷的因素。

　　而謝長華為自己的不誠實，付出的代價是無期徒刑。

根據前任納斯達克駐中國首席代表黃華國說:"企業先在OTCBB經過充分培養,待市場表現贏得投資者認同后再向主板市場攀升也不失為上策」

So after DD, I would agree this GTEC is a stock belongs to this group.

曹務波給了樓豬多少好處哈？還肉德秀涅，呵呵。

#1, No boday paid me anything!

#2. I thought this forum is for sharing,not for cursing. If you do not withdraw your wording, I would rather withdraw from this forum.

BACKCHINA讓我來當這個版主，並沒有給出什麼原則性指示。只是我的感覺是，BACKCHINA不希望藉此論壇打廣告(比如推薦有太多個人利益的小股，或者推銷產品，當然有此願望可以同BACKCHINA聯繫。比如，如果我推薦XOM，就不會是廣告，美國最大上市公司沒有小股東會推得動它的股價吧)。
當然，個人談對某一股票的想法，無論對錯，都可能有交流價值。但相互出言不遜就不值得。因為一段時間后的股價是真正的裁判員。
其他論壇，也有相互謾罵，我也反罵。但是如何決定是別的版主的事情。我希望這種事盡量不要在這個論壇出現。

Fair!

原帖由 jp8888 於 2007-12-26 09:35 發表
#1, No boday paid me anything!

,那就祝樓主套牢愉快啦！

[ 本帖最後由 華夏之聲 於 2007-12-30 11:46 編輯 ]

愛上了一個股票，就更可能會被它燙到。因為愛，就有很多不切實際的幻想，結果被
幻想欺騙了。GTEC能轉到正板市場就會好嗎？至少在可以預見的未來是不可能的。
因為在這個信貸危機的年代，經營不善的小公司都在掙扎。

可以愛一個股票一時，但是市場不愛它，這樣的醜小鴨就很難變成天鵝。